Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …

Breast cancer management has witnessed significant advancements, especially in the
diagnosis and treatment response monitoring through the implementation of imaging …

This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …

Background Endocrine therapy resistance in hormone receptor-positive/HER2-negative
(HR+/HER2−) breast cancer (BC) is a significant clinical challenge that poses several unmet …

Fat mass and obesity-associated protein (FTO), which is closely linked with obesity and
dietary intake, plays an important role in diet-related metabolic diseases. However, the …

Following the first characterization of circulating tumor DNA (ctDNA) in the 1990s, recent
advances led to its introduction in the clinics. At present, the European Society Of Medical …

PURPOSE To guide clinicians and policymakers in three global resource-constrained
settings on treating patients with metastatic breast cancer (MBC) when Maximal setting …

Activating mutations of the estrogen receptor alpha gene (ESR1) are common mechanisms
of endocrine therapy (ET) resistance in hormone receptor-positive (HR+)/Human Epidermal …

Simple Summary In breast cancer patients, a blood sample contains components from tumor
origin as well as those influenced by the tumor disease. Blood samples are being discussed …

We aimed to study the incidence and genomic spectrum of actionable alterations (AA)
detected in serial cfDNA collections from patients with metastatic breast cancer (MBC) …